ReviewFrontiers in cell and developmental biology2026
Biomaterial-based therapeutic strategies for oral submucous fibrosis.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral submucous fibrosis (OSF) is a chronic, potentially malignant oral mucosal disease driven by areca nut chewing. It is characterized by progressive collagen deposition and debilitating symptoms such as trismus and burning sensation, which severely impair quality of life and confer a risk of malignant transformation. Given the limited efficacy of current therapies, this review aims to provide a comprehensive and critical appraisal of the evolving therapeutic landscape for OSF. We summarize conventional strategies, including pharmacological, surgical and physical approaches, alongside emerging therapeutic strategies, through a comprehensive literature review and screening of historical periodicals. The analysis reveals that established treatments have inherent limitations, whereas emerging approaches, including biomaterial-based delivery systems, nucleic acid and cell-based therapies, drug-loaded microneedle patches, and preventive interventions, show promise by overcoming poor mucosal retention, limited epithelial penetration and rapid salivary clearance. Mechanistic insights and the therapeutic potential of these strategies are discussed based on preclinical evidence. We conclude that current OSF therapies have limited efficacy, underscoring the need for innovative approaches. Emerging biomaterial-based systems and targeted drug delivery hold substantial potential, but further clinical research is essential to validate their safety and effectiveness for patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.